Atlantic Commenced Construction Following Notice to Proceed From the Ontario Power Authority

TORONTO, - (http://www.financialnewsmedia.com News Alert) -  Atlantic Wind & Solar, Inc.  (OTC: AWSL) is pleased to announce the receipt of a Notice To Proceed (NTP) on another utility scale solar power plant in Ontario Canada.  The NTP was received recently from the Ontario Power Authority (OPA) and marks the point at which construction can begin.  This is a major milestone in the project development as it confirms that the local grid studies have been completed and accepted and that the grid is capable of accepting this power.  This is also the point at which many projects in Ontario have failed and were abandoned despite having OPA power purchase agreements in place.

Construction has commenced on the estimated 60-day project.

The $1.2 million utility scale project is located in the Greater Toronto Area (GTA) of Ontario . It is sized at 240 KW AC and will supply power to the grid over a 20 year period.

The solar power plant was developed by its Canadian subsidiary Atlantic Solar Inc. 

About Atlantic Wind and Solar Inc:

Atlantic is a developer of utility scale renewable energy plants with over 650 MW's of projects at various stages of development in Canada, South America and the Caribbean.

To read the full report and/or sign up for news alerts and updates visit the company's web site at: www.AtlanticWindandSolar.com.

Disclaimer: Shareholders and investors are strongly cautioned against placing undue reliance on information set forth within this website and these communications in making any investment decisions concerning our securities. The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the OTCMarkets.com including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. Nothing within this site is meant to be a solicitation to buy or sell our securities. Investing in over the counter (OTC) securities often carries a high degree of risk. Please contact your financial advisor before investing in our securities.

Atlantic Wind & Solar Inc.

Main: +1-416-900-0380 ext 321
Toll Free: +1-800-891-1657

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atlantic-commenced-construction-following-notice-to-proceed-from-the-ontario-power-authority-300069186.html

SOURCE Atlantic Wind & Solar, Inc


FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated two thousand five hundred dollars for Atlantic Wind & Solar, Inc. news coverage by the company.  FNMG HOLDS NO SHARES OF Atlantic Wind & Solar, Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements. 

Surna Reports 2014 Financial Results and Subsequent Events

BOULDER, Colo.,- (http://www.financialnewsmedia.com News Alert) - Surna Inc. (OTCQB: SRNA), is a technology company that engineers, manufactures, and distributes state-of-the art equipment and systems for controlled environment agriculture ("CEA") currently specializing in commercial indoor cannabis cultivation, announced financial results for 2014 and subsequent events.

In April 2014, the Company began operations and in its third quarter closed on its acquisition of Hydro Innovations. For the year ended December 31, 2014, the Company had gross revenues of $1,838,912 and on a combined proforma basis with Hydro Innovations it had gross revenues of $2,488,837. The net loss for the year and combined proforma loss were $2,991,969 and $3,263,320, respectively.

Surna established its foundation as a technology-based company, spending $319,430 on research development for new technology and products, accounting for 17% of the Company's revenue. The Company spent $240,784 for advertising and marketing to advance its products and brand recognition. Its general and administrative expenses were $2,636,244, which included a non-recurring one-time non-cash expense of $1,330,000.  

The Company finished the year with a balance sheet that included liquid assets (cash, accounts receivable, inventory and prepaid assets) of over $1,400,000 while current accounts payable in cash totaled $725,231, of which $303,672 is payable to shareholders. During the year, the Company raised $2,961,000 through the issuance of convertible debt and an additional $911,000 subsequent to year end. 

The Company entered 2015 with $408,200 in contracts that were in progress during 2014; corresponding revenue was deferred into 2015 pending completion of the contracts.  

"2014 was a year of building infrastructure for new technology, producing innovative new products, and establishing Surna's presence in the market," says Bryon Jorgenson, COO.

Subsequent events:

The Company announced the departure of Tom Bollich as CEO and Board Member effective April 17. It was expected that Bryon Jorgenson would succeed Bollich following his resignation; however, Jorgenson will not serve as the Company's President or Chief Executive Officer at this time, instead he will continue to serve as the Company's Chief Operating Officer. Tae Darnell will assume the position of Principle Executive Officer until the Board of Directors appoints the next Chief Executive Officer.

Darnell stated, "Tom's presence will be missed, but he put in place a creative team of engineers and staff to meet the needs of the dynamic cannabis market."

About Surna, Inc.:

Surna, Inc. (www.surna.com) develops innovative technologies and products that monitor, control or address the energy and resource intensive nature of indoor cannabis cultivation. Currently, the Company's revenue stream is based on its main product offerings – supplying industrial technology and products to commercial indoor cannabis grow facilities.

Headquartered in Boulder, CO, Surna's diverse engineering team is tasked with creating novel energy and resource efficient solutions, including the Company's signature water-cooled climate control platform. The Company's engineers continuously seek to create technology that solve the highly specific demands of the cannabis industry for temperature, humidity, light and process control.

Surna's goal is to provide intelligent solutions to improve the quality, the control and the overall yield and efficiency of indoor cannabis cultivation. The Company's operations exclude the production or sale of marijuana.

Safe Harbor Statement

This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should," "expect," "anticipate," "believe," "estimate," "intend," "plan" and other similar expressions. Our actual results, such as the Company's ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Statement About Cannabis Markets

The use, possession, cultivation, and distribution of cannabis is prohibited by federal law.  This includes medical and recreational marijuana.  Although certain states have legalized medical and recreational cannabis, companies and individuals involved in the sector are still at risk of being prosecuted by federal authorities. Further, the landscape in the cannabis industry changes rapidly.  What was the law last week is not the law today and what is the law today may not be the law next week.  This means that at any time the city, county, or state where cannabis is permitted can change the current laws and/or the federal government can supersede those laws and take prosecutorial action. Given the uncertain legal nature of the cannabis industry, it is imperative that investors understand that the cannabis industry is a high risk investment. A change in the current laws or enforcement policy can negatively affect the status and operation of our business, require additional fees, stricter operational guidelines and unanticipated shut downs.

At the Company

David Traylor
Chief Business Officer
+1-303-993-5271
david.traylor@surna.com

Investor Relations

David Kugelman
Atlanta Capital Partners, LLC
+1-404-856-9157
+1-866-692-6847 Toll Free - U.S. And Canada

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/surna-reports-2014-financial-results-and-subsequent-events-300069181.html

SOURCE Surna, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated one thousand nine hundred dollars for Surna, Inc. news coverage by the company.  FNMG HOLDS NO SHARES OF Surna, Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies

Studies to evaluate the effects of bryostatin-1 in a Fragile X Syndrome mouse model over a thirteen week period

NEWARK, N.J., - (http://www.financialnewsmedia.com News Alert) - Neurotrope, Inc. (OTCQB: NTRP) today announced that eurotrope BioScience, Inc., its wholly-owned operating subsidiary, has received a grant from the FRAXA Research Foundation, Inc. ("FRAXA") to fund a pre-clinical Fragile X Syndrome ("FXS") behavior study for its lead proprietary drug candidate, bryostatin, at FRAXA's purpose built laboratory located at the University of Chile in Santiago, Chile.

FRAXA was founded in 1994 by three parents of children with FXS to support scientific research aimed at finding a treatment and a cure for this disease. FXS is the most common cause of inherited intellectual disability and the most common known genetic cause of autism or autism spectrum disorders.  FRAXA funds grants and fellowships at universities all over the world and has funded more than $24 million in scientific research. 

Under the terms of the grant, FRAXA will provide full funding for a preclinical study to evaluate the behavioral effects of bryostatin-1 in a FXS mouse model. Bryostatin is a potent activator of Protein Kinase C (PKC), which Neurotrope believes is a viable therapeutic approach for the treatment of FXS. Preclinical research at the Blanchette Rockefeller Neurosciences Institute (BRNI), which formed the basis for Neurotrope receiving Orphan Drug Designation for bryostatin, has suggested that treatment with bryostatin can mature synapses and increase the number of synaptic connections resulting in improved learning and memory.

Neurotrope is developing bryostatin under a licensing agreement with BRNI. The Company was recently granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for bryostatin in the treatment of FXS.

"We are pleased to have received a grant from FRAXA to fund this important research as we continue working toward our goal of bringing an effective treatment to the market for patients and their families who deal with consequences of this severe genetic disorder" stated Charles S. Ramat, President and CEO of Neurotrope. "Having obtained orphan drug designation for bryostatin in FXS, we now look forward to accelerating our research efforts as we develop our clinical program.  We are excited to work with FRAXA at its laboratory in the University of Santiago to garner additional preclinical evidence of the therapeutic value for bryostatin in treating FXS."

About Fragile X Syndrome

FXS is the most common cause of inherited intellectual disability and the most common known genetic cause of autism or autism spectrum disorders. There is currently no FDA approved treatment for FXS available on the market today.  Symptoms of FXS include moderate to severe learning disabilities, behavioral disorders, seizures and cognitive impairment.  FXS is caused by a partial or a full mutation of the FMR1 gene.

About Neurotrope

Neurotrope Bioscience Inc., the operating subsidiary of Neurotrope, Inc., was formed in October 2012 principally to license, develop and commercialize various novel therapeutic and diagnostic technologies from the Blanchette Rockefeller Neuroscience Institute (BRNI) which are focused on the development of conventional small molecules that are extraordinarily potent in the activation of the enzyme PKCe.  PKCe has been shown to play a central role in the regrowth or repair of nervous tissues, cells or cell products. Neurotrope's pipeline, under its license from BRNI, includes the drug candidate, bryostatin, for the treatment of Alzheimer's disease, and a minimally invasive, diagnostic biomarker analysis system which would assess the presence of Alzheimer's in patients. In addition, Neurotrope has a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai located in New York City to utilize its proprietary information and data package for the use of bryostatin-1 in the treatment of Niemann-Pick Type C Disease, a rare disease, mostly of children who are afflicted with Alzheimer-like symptoms. Also, the Company, under its BRNI license, has the rights to develop the licensed technology for other cognitive dysfunctions, including orphan diseases, such as FXS.

About The Blanchette Rockefeller Neurosciences Institute

Located in Morgantown, WV, BRNI, at West Virginia University, is a unique, independent, non-profit institute dedicated to the study of memory and finding solutions to memory disorders. BRNI was founded in 1999 in memory of Blanchette Ferry Hooker Rockefeller, an Alzheimer's patient and mother of U. S. Senator John D. Rockefeller IV. BRNI is operated in alliance with West Virginia University as well as in collaboration with other academic institutions.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding a preclinical study evaluating the behavioral effects of bryostatin-1 in a FXS mouse model, future strategies for development of treatments for orphan diseases, building a portfolio of drug candidates for orphan diseases, suggestions of bryostatin's usefullness and potential for the diagnostic system to assess Alzheimer's disease, FXS and other cognitive dysfunctions in patients.  Such forward-looking statements are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, significant government regulation of pharmaceuticals and the healthcare industry, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The Company does not undertake to update these forward-looking statements.

Please visit www.neurotropebioscience.com for further information.

For additional information, please contact:

Robert Weinstein
Chief Financial Officer
+1-973-242-0005
rweinstein@neurotropebioscience.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurotrope-receives-research-grant-from-the-fraxa-research-foundation-to-fund-pre-clinical-fragile-x-syndrome-behavioral-studies-300068336.html

SOURCE Neurotrope, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated two thousand dollars for Neurotrope, Inc. news coverage by the company.  FNMG HOLDS NO SHARES OF Neurotrope, Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

MagneGas Signs Joint Venture for Major Expansion of Subsidiary, "Equipment Sales And Services Inc."

TAMPA, Fla., - (http://www.financialnewsmedia.com News Alert) - MagneGas Corporation ("MagneGas" or the "Company") (NASDAQ: MNGA) is a leading technology company. Included in the Company's IP portfolio is a patented process that converts liquid waste into MagneGas® fuel. Today the Company announced that its subsidiary, Equipment Sales and Services Inc. (ESSI) has signed a contract to open a sales and service outlet into North Central Florida.

A 50/50 joint venture was established with Suwannee Ironworks ("Suwannee"), an existing client. This allows for the distribution of MagneGas® in areas not currently serviced by the Company, as well as opening up additional potential revenue opportunities from gas and welding supplies. The expanded location also allows MagneGas to capitalize on authorized distributor contracts with Lincoln and Miller, which would not be possible without an already an existing distributorship.  The Company expects that this new joint venture will launch MagneGas® into North Florida, from Tallahassee to Jacksonville, as well as from Southern Georgia to Gainesville, FL.  MagneGas's subsidiary, ESSI, will provide the inventory, proprietary distributorships, accounting and billing management while Suwanee will provide the commercial location, shipping, transportation, and personnel to operate the new location for the joint venture.  The Company believes this will allow them to service existing MagneGas clients with all their industrial needs which was previously difficult due to distance..

"ESSI was purchased as a platform to not only sell MagneGas®, but to service industrial welding needs as well. Our new location will allow us to service existing MagneGas clients which was previously impracticable due to distance," stated Jack Armstrong, Executive Vice President Operations for MagneGas and ESSI.  "We purchased ESSI to expand MagneGas sales and growth. Many clients prefer a 'one stop shop' and having a local physical location should attract additional clients to MagneGas® fuel. The official opening is scheduled for July 1 but our sales and marketing efforts have already commenced."

Ernie Caparelli, one of the owners of Suwanee Ironworks, commented, "Through our many business relationships in the area, we anticipated being able to provide a significant impact on MagneGas's sales growth and service in this new market. Local knowledge is critical to success in North Florida.  Suwannee Ironworks has been in business for over 30 years and our long standing contacts will allow us to gain immediate traction in the market."

Brian Linton, owner of The Recycling Center, Inc. stated, "The Recycling Center has used MagneGas®  for our scrap yards since 2012 and we love the gas.   We have multiple locations and locally we feel comfortable allowing ESSI to supply us with MagneGas®.   We are always looking to expand and would love for ESSI to transition into other gases, safety products and hard goods."

The MagneGas IR App is now available for free in Apple's App Store for the iPhone or iPad http://bit.ly/AfLYww and at Google Play http://bit.ly/Km2iyk for Android mobile devices.

To be added to the MagneGas investor email list, please email pcarlson@kcsa.com with MNGA in the subject line.

About MagneGas Corporation

Founded in 2007, Tampa-based MagneGas Corporation (NASDAQ: MNGA) is a technology Company that counts among its inventions, a patented process that converts liquid waste into hydrogen based fuels.  The Company currently sells MagneGas® into the metal working market as a replacement to acetylene.  It also sells equipment for the sterilization of bio-contaminated liquid waste for various industrial and agricultural markets.  In addition, the Company is developing a variety of ancillary uses for MagneGas® fuels utilizing its high flame temperature for co-combustion of hydrocarbon fuels and other advanced applications.  For more information on MagneGas, please visit the Company's website at www.MagneGas.com.

About Suwannee Ironworks

Suwannee Ironworks and Fence was founded in 1990. With over 40 years of experience. The Company's goal is to provide clients with the highest quality in fabrication and fencing needs. Their top priority is quality work and personal service no matter how big or small the project may be. Suwannee Iron Works & Fence fabricates and installs structural steel framing and miscellaneous components involved in building large and small commercial and industrial projects such as Office Buildings, Department Stores and Warehouses throughout the United States. Their designers, engineers, and fabricators regularly work with carbon steel, stainless steel, aluminum, titanium, and magnesium. Their sister company, Suwannee Fence also supplies installs chain link, wroth iron, PVC & wood fencing custom built to the project.  The Company's wide-ranging steel fabricating qualifications have made them a custom steel fabricator of choice for manufacturers throughout the United States. They have built a reputation on quality workmanship and integrity in all aspects of business. They are proud of their longevity and expect to maintain their status as a leader in the custom steel fabricating industry. The Company supplies and installs products from Maine to Hawaii and from Puerto Rico to Alaska.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/magnegas-signs-joint-venture-for-major-expansion-of-subsidiary-equipment-sales-and-services-inc-300066838.html

SOURCE MagneGas Corporation

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which iis a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated three thousand five hundred dollars for MagneGas Corp. news coverage by the company.  FNMG HOLDS NO SHARES OF MagneGas Corp.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome

NEWARK, N.J.,- (http://www.financialnewsmedia.com News Alert) - Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope BioScience, Inc., its wholly-owned operating subsidiary, (the "Company") has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its lead proprietary drug candidate, bryostatin, in the treatment of Fragile X Syndrome (FXS).

Bryostatin is a potent activator of Protein Kinase C (PKC), which the Company believes is a viable therapeutic approach for the treatment of Fragile X Syndrome.  Neurotrope is developing bryostatin under a licensing agreement with the Blanchette Rockefeller Neuroscience Institute (BRNI).

"We are pleased to have received orphan drug designation for bryostatin for the treatment of FXS which represents an area of significant unmet need for patients and families who live with the consequences of this genetic disorder," said Charles S. Ramat, President and Chief Executive Officer of Neurotrope, Inc. "One of the key strategies for our Company's future is the licensing of novel therapeutics to develop treatments for orphan diseases such as FXS.   In keeping with this strategic imperative, we have also initiated preclinical work with bryostatin for the treatment of Niemann-Pick type C, a rare devastating genetic disorder in children.  As we progress our clinical development programs for Fragile X and NPC we continue to work towards building a robust portfolio of drug development candidates in orphan disease indications."

Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act (PDUFA) filing fees. The OOPD also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.

Also commenting on the announcement, Dr. Daniel Alkon, Scientific Director of BRNI and Chief Scientific Officer of Neurotrope BioScience, Inc., stated, "We are very encouraged by the pre-clinical data we acquired in a Fragile X mouse study that suggests treatment with bryostatin can mature synapses and increase the number of synaptic connections resulting in improved learning and memory." 

About Fragile X Syndrome

FXS is the most common cause of inherited intellectual disability and the most common known genetic cause of autism or autism spectrum disorders. There is currently no FDA approved treatment for FXS available on the market today.  Symptoms of FXS include moderate to severe learning disabilities, behavioral disorders, seizures and cognitive impairment.  FXS is caused by a partial or a full mutation of the FMR1 gene.

About Neurotrope

Neurotrope Bioscience Inc., the operating subsidiary of Neurotrope, Inc., was formed in October 2012 principally to license, develop and commercialize various novel therapeutic and diagnostic technologies from the Blanchette Rockefeller Neuroscience Institute (BRNI) which are focused on the development of conventional small molecules that are extraordinarily potent in the activation of the enzyme PKCe.  PKCe has been shown to play a central role in the regrowth or repair of nervous tissues, cells or cell products. Neurotrope's pipeline, under its license from BRNI, includes the drug candidate, bryostatin, for the treatment of Alzheimer's disease, and a minimally invasive, diagnostic biomarker analysis system which would assess the presence of Alzheimer's in patients. In addition, Neurotrope has a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai located in New York City to utilize its proprietary information and data package for the use of bryostatin-1 in the treatment of Niemann-Pick Type C Disease, a rare disease, mostly of children who are afflicted with Alzheimer-like symptoms. Also, the Company, under its BRNI license, has the rights to develop the licensed technology for other cognitive dysfunctions, including orphan diseases, such as Fragile X Syndrome.

About The Blanchette Rockefeller Neurosciences Institute

Located in Morgantown, WV, BRNI, at West Virginia University, is a unique, independent, non-profit institute dedicated to the study of memory and finding solutions to memory disorders. BRNI was founded in 1999 in memory of Blanchette Ferry Hooker Rockefeller, an Alzheimer's patient and mother of U. S. Senator John D. Rockefeller IV. BRNI is operated in alliance with West Virginia University as well as in collaboration with other academic institutions.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding future strategies for development of treatments for orphan diseases, building a portfolio of drug candidates for orphan diseases, suggestions of bryostatin's usefullness and potential for the diagnostic system to assess Alzheimer's disease in patients.  Such forward- looking statements are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, significant government regulation of pharmaceuticals and the healthcare industry, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The Company does not undertake to update these forward-looking statements.

Please visit www.neurotropebioscience.com for further information.

For additional information, please contact:

Robert Weinstein
Chief Financial Officer
+1-973-242-0005
rweinstein@neurotropebioscience.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurotrope-receives-fda-orphan-drug-designation-for-bryostatin-in-the-treatment-of-fragile-x-syndrome-300063444.html

SOURCE Neurotrope, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated two thousand dollars for Neurotrope, Inc. news coverage by the company.  FNMG HOLDS NO SHARES OF Neurotrope, Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease

NEWARK, N.J., - (http://www.financialnewsmedia.com News Alert) -Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the "Company") has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the Company's compound bryostatin-1 for the treatment of Alzheimer's disease.  WCT is a leading global clinical research organization with substantial experience in conducting trials in Alzheimer's disease.

The Company and WCT signed a letter of intent on March 30, 2015 outlining the scope of the services that WCT will provide. The Company will pay WCT approximately $300,000 for the services and related third-party costs.

Neurotrope Bioscience plans to submit its protocol to the FDA for this clinical trial in approximately 150 patients with moderately severe to severe Alzheimer's disease early in the second quarter of 2015.  The Company expects to begin enrollment for the six month study sometime during the third quarter pending the FDA's review of the protocol, and plans to enter into a definitive agreement with WCT for services related to the study at the appropriate time subject to available resources.

Neurotrope Bioscience has an exclusive license to develop and commercialize bryostatin, a potent modulator of an enzyme called protein kinase C epsilon (PKCe), which has been studied extensively by the Blanchette Rockefeller Neurosciences Institute (BRNI) as a possible treatment of cognitive disorders. Based upon a number of BRNI pre-clinical and autopsy-validated human tissue studies, PKCe deficits have been implicated as a potential cause of Alzheimer's disease. The Company is approaching the treatment of Alzheimer's disease through the activation of PKCe.  In animal models of Alzheimer's disease, activation of PKCe has been shown to improve learning and memory, induce synaptogenesis or growth of new synapses and prevent neuronal death.

Charles S. Ramat, President and Chief Executive Officer of Neurotrope, Inc. commented on the selection: "We are extremely pleased to have entered into a letter of intent with WCT to conduct the activities required prior to enrolling patients for our planned Phase 2b Alzheimer's trial in moderately severe to severe Alzheimer's patients.   WCThas strong relationships with numerous clinical sites with experience in Alzheimer's disease and possesses a great expertise in conducting Alzheimer's clinical trials which is critical to Neurotrope as we move through this important process.  We are confident that they will play a key role for us throughout bryostatin's clinical development as we continue to move towards its eventual commercialization for the treatment of this debilitating disease."

About Neurotrope's Approach to Alzheimer's

In contrast to the industry's historic focuses on removal of amyloid plaque and Tau pathology in the brain – which have resulted in numerous, failed clinical trials – Neurotrope is following a new and novel approach. Specifically, research conducted in animal models by the Company's Chief Scientific Officer, Dr. Dan Alkon, of the Blanchette Rockefeller Neurosciences Institute, has shown that PKCe, when stimulated, initiates a cascade of enzymatic events, ultimately improves synaptic function, induces formation of new synapses and inhibits cell death. The stimulation of PKCe is far upstream from the formation of plaques and tangles, which may be considered pathologic markers of AD, rather than causes. As a potent modulator of PKCe at low dose levels, bryostatin has been shown to stimulate this key enzyme, thus showing promise in restoring memory and learning function.

About Worldwide Clinical Trials


Worldwide Clinical Trials balances science, medicine, operational and commercial intelligence with strategic insight to manage drug development programs in nearly 60 countries. WCT combines recognized therapeutic expertise – most notably in central nervous system, cardiovascular and oncology clinical trial methodologies – with robust global operating and technology platforms, consultative leadership and a deep commitment to each client's unique needs to foster successful development of life-changing medicines. For more information on the company's Phase I-IV clinical trial services, visit wwctrials.com.

About Neurotrope

Neurotrope Bioscience Inc., the operating subsidiary of Neurotrope, Inc., was formed in October 2012 principally to license, develop and commercialize various novel therapeutic and diagnostic technologies from the Blanchette Rockefeller Neuroscience Institute (BRNI) which are focused on the development of conventional small molecules that are extraordinarily potent in the activation of the enzyme PKCe.  PKCe has been shown to play a central role in the regrowth or repair of nervous tissues, cells or cell products. Neurotrope's pipeline, under its license from BRNI, includes the drug candidate, bryostatin, for the treatment of Alzheimer's disease, and a minimally invasive, diagnostic biomarker analysis system which would assess the presence of Alzheimer's in patients. In addition, Neurotrope has a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai located in New York City to utilize its proprietary information and data package for the use of bryostatin-1 in the treatment of Niemann-Pick Type C Disease, a rare disease, mostly of children who are afflicted with Alzheimer-like symptoms. Also, the Company, under its BRNI license, has the rights to develop the licensed technology for other cognitive dysfunctions, including orphan diseases, such as Fragile X Syndrome.

About The Blanchette Rockefeller Neurosciences Institute

Located in Morgantown, WV, BRNI, at West Virginia University, is a unique, independent, non-profit institute dedicated to the study of memory and finding solutions to memory disorders. BRNI was founded in 1999 in memory of Blanchette Ferry Hooker Rockefeller, an Alzheimer's patient and mother of U. S. Senator John D. Rockefeller IV. BRNI is operated in alliance with West Virginia University as well as in collaboration with other academic institutions.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the payment for services to WCT, the plans and scope for the Company's next clinical trial with bryostatin in the treatment of Alzheimer's disease, timing of submission of the protocol and enrollment of patients in the trial, timing for completion of the study, and potential for the diagnostic system to assess Alzheimer's disease in patients.  Such forward- looking statements are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, significant government regulation of pharmaceuticals and the healthcare industry, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The Company does not undertake to update these forward-looking statements.

Please visit www.neurotropebioscience.com for further information.

For additional information, please contact:
Robert Weinstein
Chief Financial Officer
+1-973-242-0005
rweinstein@neurotropebioscience.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurotrope-selects-worldwide-clinical-trials-to-commence-services-for-phase-2b-trial-of-bryostatin-for-the-treatment-of-alzheimers-disease-300061121.html

SOURCE Neurotrope, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated two thousand five hundred dollars for Neurotrope, Inc. news coverage by the company.  FNMG HOLDS NO SHARES OF Neurotrope, Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

U-Vend, Inc. Signs Multi-Year Licensing Agreement With National Hockey League (NHL)

Licensing Agreement Includes Exclusive NHL Team-Branded 'Pucks Premium Ice Cream' Product

SANTA MONICA, CA, - (http://www.financialnewsmedia.com News Alert) - U-Vend, Inc. (OTCQB: UVND), a consumer products and technology company that develops, distributes, and markets next-generation self-serve electronic kiosks announced today a multi-year, North American licensing agreement with the National Hockey League. The agreement includes usage of NHL(R) team branded marks on U-Vend, Inc.'s 'Puck Premium Ice Cream(TM).' 

This summer, fans across Canada will be able to purchase puck-shaped ice cream bars featuring NHL-branded hockey stick-shaped sticks from retail freezer merchandisers, located in convenience stores and large national retail grocery stores. Beginning in the summer of 2016, the 'Pucks Premium Ice Cream(TM)' product will expand to the United States, and will be available to fans from vending machines and self-serve kiosk freezers in both countries.

"Our new partnership with the National Hockey League -- a global brand -- is a significant event for U-Vend. We are very excited to not only be named the Official Ice Cream of the NHL, but to also be joining an elite group in the NHL family," stated Raymond Meyers, CEO of U-Vend, Inc. "This partnership affords tremendous opportunities for us to amplify our brand. We are looking forward to a long and successful relationship with the NHL."

Unique to U-Vend, these ice cream pucks will be available in specialty self-serve vending machines and 'grab-and-go' kiosks, each with built-in digital product and advertising screens and featuring NHL branding. Both machines will carry the team-branded Pucks Premium ice cream exclusively.

"U-Vend is a great addition to the NHL's thriving roster of licensees, with exclusivity in a unique category for us," said Barry Monaghan, NHL VP, Retail Sales and Marketing. "Their NHL-branded product is perfect for the League's passionate hockey fans, who consume the game year-round."

"We believe we have created a strong and multi-faceted marketing engine with the introduction of the Pucks brand," said Paul Neelin, Founder of U-Vend and Chief Operating Officer. "Not only are we able to brand the outside wrapper of the Pucks ice cream bar, but we'll also print NHL team marks on the mini hockey stick that is inserted into the ice cream Puck, making it very collectable."

ABOUT U-VEND, INC. U-Vend, Inc. is headquartered in Santa Monica, CA, with additional locations in Stoney Creek, Ontario Canada, Chicago, IL., and Las Vegas, NV. U-Vend develops, distributes and markets various next-generation, self-serve electronic kiosks in a variety of retail locations in North America. The Company owns and operates kiosks and has partnered with numerous national consumer product companies such as Mini Melts USA, Del Monte and Arthur's Smoothies, to deliver new and unique customer retail experiences in an automated setting.

For more information on U-Vend, visit www.u-vend.com.

U-Vend, Inc. TWITTER U-Vend, Inc. FACEBOOK

ABOUT THE NHL The National Hockey League (NHL(R)), founded in 1917, consists of 30 Member Clubs, each reflecting the League's international makeup with players from more than 20 countries represented on team rosters, vying for the most cherished and historic trophy in professional sports -- the Stanley Cup(R). Every year the NHL entertains more than 250 million fans in-arena and through its partners on national television and radio; more than 10 million fans on its social platforms; and more than 300 million fans online at NHL.com. In Canada, the 2014-15 season marks the beginning of a landmark 12-year broadcast and multimedia agreement with Rogers Communications, which includes national rights to NHL games on all platforms in all languages. In the U.S., the NHL is in the fourth season of its 10-year agreement with NBC and NBCSN, the 10th consecutive season both networks have served as national television partners. The NHL is committed to giving back to the community with programs including: Hockey is for Everyone(TM), which supports nonprofit youth hockey organizations across North America; Hockey Fights Cancer(TM), raising money for local and national cancer organizations; NHL Green(TM), which is committed to pursuing sustainable business practices; and a partnership with the You Can Play Project, which is committed to supporting the LGBT community and fighting homophobia in sports. The NHL received three 2014 Sports Business Awards: "Sports League of the Year," "Sports Executive of the Year" recognizing Commissioner Gary Bettman, and "Sports Event of the Year" for the 2014 Bridgestone NHL Winter Classic(R). For more information, visit NHL.com.

NHL, and the NHL Shield, are trademarks of the National Hockey League. Copyright NHL 2015. All Rights Reserved.

FORWARD LOOKING STATEMENTS Certain statements contained in this news release regarding matters that are not historical facts may be forward-looking statements. Because such forward-looking statements include risks and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties pertaining to market acceptance for the Company's products and services, its ability to succeed in increasing revenues in the near term to attain profitable operations and generate sufficient cash flow from operations, the effect of new competitors in its markets, its integration of acquired businesses, and other risk factors identified from time to time in its filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and current reports on Form 8-K which are available at the SEC's website www.sec.gov. Other factors not currently anticipated may also materially and adversely affect U-Vend's results of operations, financial position, and cash flows. There can be no assurance that future results will meet expectations. While the Company believes that the forward-looking statements in this news release are reasonable, the reader should not place undue reliance on any forward-looking statement. In addition, these statements speak only as of the date made. The Company does not undertake, and expressly disclaims any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.


For more information, please contact:

U-Vend, Inc.
Corporate Office
(855) 55-UVEND

Investor Relations
(855) 55-UVEND, ext. 3

SOURCE: U-Vend, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which iis a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated two thousand dollars for U-Vend, Inc. news coverage by the company.  FNMG HOLDS NO SHARES OF U-Vend, Inc..

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.